BRCA2 carriers were significantly less likely to be ever users of hormone replacement therapy (HRT) than non‐BRCA breast cancer patients (26.2% vs 53.8%) (eTable 6 in Data Supplement 1, Supporting Information). Here, BRCA2 is linked to breast carcinoma.